CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno Sells 1,198 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

CRISPR Therapeutics Price Performance

CRSP opened at $41.99 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $75.91. The firm has a market capitalization of $3.60 billion, a PE ratio of -9.61 and a beta of 1.77. The company’s 50-day moving average is $43.03 and its 200 day moving average is $45.63.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CRSP. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus decreased their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Morgan Stanley boosted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $73.11.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Wood Tarver Financial Group LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $30,000. Ameriflex Group Inc. bought a new position in CRISPR Therapeutics in the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP lifted its stake in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.